3
10/13/2015 Gallstones (Cholelithiasis) Medication: Gallstone Dissolution Agents http://emedicine.medscape.com/article/175667medication 1/3 Gallstones (Cholelithiasis) Medication Author: Douglas M Heuman, MD, FACP, FACG, AGAF; Chief Editor: Julian Katz, MD more... Updated: Jan 20, 2015 Medication Summary Medical dissolution of gallstones may be attempted with administration of ursodiol. Gallstone Dissolution Agents Class Summary These agents suppress hepatic cholesterol secretion and inhibit intestinal absorption of cholesterol. Ursodiol is the most common drug used. It solubilizes cholesterol in micelles and acts by dispersing cholesterol in aqueous media. View full drug information Ursodiol (Actigall, Urso 250, Urso Forte) Ursodiol (ursodeoxycholic acid) is indicated for radiolucent noncalcified gallbladder stones smaller than 20 mm in diameter when conditions preclude cholecystectomy. Ursodiol suppresses hepatic secretion and inhibits intestinal absorption. It appears to have little inhibitory effect on the synthesis and secretion into bile of endogenous bile acids and does not appear to affect secretion of phospholipids into bile. After repeated doses, the drug reaches steadystate bile concentrations in about 3 weeks. Cholesterol is insoluble in aqueous media, but it can be solubilized in at least 2 different ways in the presence of dihydroxy bile acids. In addition to solubilizing cholesterol in micelles, ursodiol acts by dispersing cholesterol as liquid crystals in aqueous media. The overall effect of ursodiol is to increase the concentration level at which saturation of cholesterol occurs. The various actions of ursodiol combine to change the bile of patients with gallstones from cholesterolprecipitating to cholesterolsolubilizing bile, thus resulting in bile conducive to cholesterol stones dissolution. Contributor Information and Disclosures Author Douglas M Heuman, MD, FACP, FACG, AGAF Chief of Hepatology, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, American Gastroenterological Association Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer for other; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol Myers Squibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other; Received grant/research funds from MannKind for other. Coauthor(s) Jeff Allen, MD Assistant Professor, Department of Surgery, University of Louisville Disclosure: Nothing to disclose. Anastasios A Mihas, MD, DMSc, FACP, FACG Professor, Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine; Consulting Staff, Virginia Commonwealth University Hospitals and Clinics; Chief of GI Clinical Research, Director of GI Outpatient Service, Associate Director of Hepatology, Hunter Holmes McGuire Veterans Affairs Medical Center Anastasios A Mihas, MD, DMSc, FACP, FACG is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Sigma Xi, Southern Society for Clinical Investigation, American Federation for Clinical Research, Gastroenterology Research Group Disclosure: Nothing to disclose. Chief Editor Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility Disclosure: Nothing to disclose. Acknowledgements Firass Abiad, MD Head of Division, General and Laparoscopic Surgery, Specialized Medical Center Hospital, Saudi Arabia Disclosure: Nothing to disclose.

Gallstones (Cholelithiasis) Medication_ Gallstone Dissolution Agents

  • Upload
    mmmm

  • View
    221

  • Download
    1

Embed Size (px)

DESCRIPTION

http://emedicine.medscape.com/article/175667-overview

Citation preview

Page 1: Gallstones (Cholelithiasis) Medication_ Gallstone Dissolution Agents

10/13/2015 Gallstones (Cholelithiasis) Medication: Gallstone Dissolution Agents

http://emedicine.medscape.com/article/175667medication 1/3

Gallstones (Cholelithiasis) MedicationAuthor: Douglas M Heuman, MD, FACP, FACG, AGAF; Chief Editor: Julian Katz, MD more...

Updated: Jan 20, 2015

Medication SummaryMedical dissolution of gallstones may be attempted with administration of ursodiol.

Gallstone Dissolution Agents

Class Summary

These agents suppress hepatic cholesterol secretion and inhibit intestinal absorptionof cholesterol. Ursodiol is the most common drug used. It solubilizes cholesterol inmicelles and acts by dispersing cholesterol in aqueous media.

View full drug information

Ursodiol (Actigall, Urso 250, Urso Forte)

Ursodiol (ursodeoxycholic acid) is indicated for radiolucent noncalcified gallbladderstones smaller than 20 mm in diameter when conditions preclude cholecystectomy.Ursodiol suppresses hepatic secretion and inhibits intestinal absorption. It appearsto have little inhibitory effect on the synthesis and secretion into bile of endogenousbile acids and does not appear to affect secretion of phospholipids into bile. Afterrepeated doses, the drug reaches steadystate bile concentrations in about 3 weeks.Cholesterol is insoluble in aqueous media, but it can be solubilized in at least 2different ways in the presence of dihydroxy bile acids. In addition to solubilizingcholesterol in micelles, ursodiol acts by dispersing cholesterol as liquid crystals inaqueous media. The overall effect of ursodiol is to increase the concentration levelat which saturation of cholesterol occurs.

The various actions of ursodiol combine to change the bile of patients withgallstones from cholesterolprecipitating to cholesterolsolubilizing bile, thusresulting in bile conducive to cholesterol stones dissolution.

Contributor Information and DisclosuresAuthorDouglas M Heuman, MD, FACP, FACG, AGAF Chief of Hepatology, Hunter Holmes McGuire Department ofVeterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology,Virginia Commonwealth University School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: AmericanAssociation for the Study of Liver Diseases, American College of Physicians, American GastroenterologicalAssociation

Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer forother; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol MyersSquibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other;Received grant/research funds from MannKind for other.

Coauthor(s)Jeff Allen, MD Assistant Professor, Department of Surgery, University of Louisville

Disclosure: Nothing to disclose.

Anastasios A Mihas, MD, DMSc, FACP, FACG Professor, Department of Medicine, Division ofGastroenterology, Virginia Commonwealth University School of Medicine; Consulting Staff, VirginiaCommonwealth University Hospitals and Clinics; Chief of GI Clinical Research, Director of GI Outpatient Service,Associate Director of Hepatology, Hunter Holmes McGuire Veterans Affairs Medical Center

Anastasios A Mihas, MD, DMSc, FACP, FACG is a member of the following medical societies: AmericanAssociation for the Study of Liver Diseases, American College of Gastroenterology, American College ofPhysicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, SigmaXi, Southern Society for Clinical Investigation, American Federation for Clinical Research, GastroenterologyResearch Group

Disclosure: Nothing to disclose.

Chief EditorJulian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology,American College of Physicians, American Gastroenterological Association, American Geriatrics Society,American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law,Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for SocialResponsibility

Disclosure: Nothing to disclose.

AcknowledgementsFirass Abiad, MD Head of Division, General and Laparoscopic Surgery, Specialized Medical Center Hospital,Saudi Arabia

Disclosure: Nothing to disclose.

Page 2: Gallstones (Cholelithiasis) Medication_ Gallstone Dissolution Agents

10/13/2015 Gallstones (Cholelithiasis) Medication: Gallstone Dissolution Agents

http://emedicine.medscape.com/article/175667medication 2/3

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College ofMedicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of LiverDiseases, American College of Gastroenterology, American Gastroenterological Association, and AmericanSociety for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

David Eric Bernstein, MD Director of Hepatology, North Shore University Hospital; Professor of ClinicalMedicine, Albert Einstein College of Medicine

David Eric Bernstein, MD is a member of the following medical societies: American Association for the Study ofLiver Diseases, American College of Gastroenterology, American College of Physicians, AmericanGastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine,Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western ReserveUniversity School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha,American Academy of Emergency Medicine, American College of Chest Physicians, American College ofEmergency Physicians, American College of Physicians, American Heart Association, American ThoracicSociety, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, andSociety for Academic Emergency Medicine

Disclosure: Nothing to disclose.

David FM Brown, MD Associate Professor, Division of Emergency Medicine, Harvard Medical School; ViceChair, Department of Emergency Medicine, Massachusetts General Hospital

David FM Brown, MD is a member of the following medical societies: American College of EmergencyPhysicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

William K Chiang, MD Associate Professor, Department of Emergency Medicine, New York University Schoolof Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology,American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Alfred Cuschieri, MD, ChM, FRSE, FRCS, Head, Professor, Department of Surgery and Molecular Oncology,University of Dundee, UK

Disclosure: Nothing to disclose.

Imad S Dandan, MD Consulting Surgeon, Department of Surgery, Trauma Section, Scripps Memorial Hospital

Imad S Dandan, MD is a member of the following medical societies: American Association for the Surgery ofTrauma, American College of Surgeons, American Medical Association, American Trauma Society, CaliforniaMedical Association, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

David Greenwald, MD Associate Professor of Clinical Medicine, Fellowship Program Director, Department ofMedicine, Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine

David Greenwald, MD is a member of the following medical societies: Alpha Omega Alpha, American College ofGastroenterology, American College of Physicians, American Gastroenterological Association, American Societyfor Gastrointestinal Endoscopy, and New York Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Eugene Hardin, MD, FAAEM, FACEP Former Chair and Associate Professor, Department of EmergencyMedicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine,Martin Luther King Jr/Drew Medical Center

Disclosure: Nothing to disclose.

Faye Maryann Lee, MD Staff Physician, Department of Emergency Medicine, New York University/BellevueHospital Center

Faye Maryann Lee, MD is a member of the following medical societies: Phi Beta Kappa

Disclosure: Nothing to disclose.

Sally Santen, MD Program Director, Assistant Professor, Department of Emergency Medicine, VanderbiltUniversity

Sally Santen, MD is a member of the following medical societies: American College of Emergency Physiciansand Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Assaad M Soweid, MD, FASGE, FACG Associate Professor of Clinical Medicine, Endosonography andAdvanced Therapeutic Endoscopy, Director, EndoscopyBronchoscopy Unit, Division of Gastroenterology,Department of Internal Medicine, American University of Beirut Medical Center, Lebanon

Assaad M Soweid, MD, FASGE, FACG is a member of the following medical societies: American College ofGastroenterology, American College of Physicians, American College of PhysiciansAmerican Society of InternalMedicine, American Gynecological and Obstetrical Society, and American Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center Collegeof Pharmacy; EditorinChief, Medscape Drug Reference

Page 3: Gallstones (Cholelithiasis) Medication_ Gallstone Dissolution Agents

10/13/2015 Gallstones (Cholelithiasis) Medication: Gallstone Dissolution Agents

http://emedicine.medscape.com/article/175667medication 3/3

Medscape Reference © 2011 WebMD, LLC

Disclosure: Medscape Salary Employment

References

1. Heuman DM, Moore EL, Vlahcevic ZR. Pathogenesis and dissolution of gallstones. Zakim D, Boyer TD,eds. Hepatology: A Textbook of Liver Disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1996. 1996: 376417.

2. Center SA. Diseases of the gallbladder and biliary tree. Vet Clin North Am Small Anim Pract. 2009 May.39(3):54398. [Medline].

3. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006 Jul 15.368(9531):2309. [Medline].

4. Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O, et al. Genotypephenotype relationships in the lowphospholipid associated cholelithiasis syndrome. A study of 156consecutive patients. Hepatology. 2013 Mar 26. [Medline].

5. Halldestam I, Kullman E, Borch K. Incidence of and potential risk factors for gallstone disease in a generalpopulation sample. Br J Surg. 2009 Nov. 96(11):131522. [Medline].

6. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21stcentury?. Curr Gastroenterol Rep. 2005 May. 7(2):13240. [Medline].

7. Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQ. New insights into the molecular mechanismsunderlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta. 2009 Nov.1791(11):103747. [Medline]. [Full Text].

8. Gilani SN, Bass G, Leader F, Walsh TN. Collins' sign: validation of a clinical sign in cholelithiasis. Ir J MedSci. 2009 Aug 14. [Medline].

9. Zaliekas J, Munson JL. Complications of gallstones: the Mirizzi syndrome, gallstone ileus, gallstonepancreatitis, complications of "lost" gallstones. Surg Clin North Am. 2008 Dec. 88(6):134568, x. [Medline].

10. Dauer M, Lammert F. Mandatory and optional function tests for biliary disorders. Best Pract Res ClinGastroenterol. 2009. 23(3):44151. [Medline].

11. [Guideline] Katz DS, Rosen MP, Blake MA, et al; and Expert Panel on Gastrointestinal Imaging. ACRAppropriateness Criteria® right upper quadrant pain. [online publication]. Reston (VA): American College ofRadiology (ACR). [Full Text].

12. Shapiro T, Melzer E, Binder Y, Keter D, Zbar A, Miller R, et al. Selective Utilization of PreOperativeEndoscopic Ultrasound to Exclude Choledocholithiasis Prior to Laparoscopic Cholecystectomy: ARetrospective Study. Hepatogastroenterology. 2013 May 1. 60(123):[Medline].

13. Yao CC, Huang SM, Lin CC, Ho LC, Chang SW, Chen HM, et al. Assessment of common bile duct usinglaparoscopic ultrasound during laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech. 2009Aug. 19(4):31720. [Medline].

14. Mahid SS, Jafri NS, Brangers BC, Minor KS, Hornung CA, Galandiuk S. Metaanalysis of cholecystectomyin symptomatic patients with positive hepatobiliary iminodiacetic acid scan results without gallstones. ArchSurg. 2009 Feb. 144(2):1807. [Medline].

15. [Guideline] NIH stateofthescience statement on endoscopic retrograde cholangiopancreatography(ERCP) for diagnosis and therapy. NIH Consens State Sci Statements. 2002 Jan 1416. 19(1):126.[Medline].

16. Binenbaum SJ, Teixeira JA, Forrester GJ, Harvey EJ, Afthinos J, Kim GJ, et al. Singleincisionlaparoscopic cholecystectomy using a flexible endoscope. Arch Surg. 2009 Aug. 144(8):7348. [Medline].

17. Ghazal AH, Sorour MA, ElRiwini M, ElBahrawy H. Singlestep treatment of gall bladder and bile ductstones: a combined endoscopiclaparoscopic technique. Int J Surg. 2009 Aug. 7(4):33846. [Medline].

18. Schirmer BD, Winters KL, Edlich RF. Cholelithiasis and cholecystitis. J Long Term Eff Med Implants.2005. 15(3):32938. [Medline].

19. [Guideline] Overby DW, Apelgren KN, Richardson W, Fanelli R. SAGES guidelines for the clinicalapplication of laparoscopic biliary tract surgery. Surg Endosc. 2010 Oct. 24(10):236886. [Medline]. [FullText].

20. Dan DV, Harnanan D, Maharaj R, Seetahal S, Singh Y, Naraynsingh V. Laparoscopic cholecystectomy:analysis of 619 consecutive cases in a Caribbean setting. J Natl Med Assoc. 2009 Apr. 101(4):35560.[Medline].

21. Gurusamy K, Sahay SJ, Burroughs AK, Davidson BR. Systematic review and metaanalysis ofintraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and suspectedcommon bile duct stones. Br J Surg. 2011 Jul. 98(7):90816. [Medline].

22. Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter ofoddi disorders. Gastroenterology. 2006 Apr. 130(5):1498509. [Medline].

23. Anderloni A, Ballarè M, Pagliarulo M, Conte D, Galeazzi M, Orsello M, et al. Prospective evaluation ofearly endoscopic ultrasonography for triage in suspected choledocholithiasis: Results from a large singlecentre series. Dig Liver Dis. 2013 Dec 28. [Medline].

24. Reuters Health. Endoscopic ultrasound a good first step when gallstones are suspected. Medscape MedicalNews. January 10, 2014. Available at http://www.medscape.com/viewarticle/819024. Accessed: January20, 2014.